Top Banner
Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting Author), Rohit Shetty, DNB, FRCS; Harsha Nagaraj, MS; Luci Kaweri, MD; Chetna Sharma, MS; Natasha K. Pahuja, DOMS Narayana Nethralaya, Bangalore, INDIA
12

Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Jan 15, 2016

Download

Documents

Aiyana Tuckness
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do?

None of the authors have any fi nancial disclosure to make

Vishal Vohra,MS (Presenting Author), Rohit Shetty, DNB, FRCS; Harsha Nagaraj, MS; Luci Kaweri, MD; Chetna

Sharma, MS; Natasha K. Pahuja, DOMS

Narayana Nethralaya, Bangalore, INDIA

Page 2: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

PURPOSETo evaluate the dual role of crosslinking both as a treatment modality and a pathogenic factor for microbial keratitis

Group 1 To evaluate the efficacy and safety of corneal collagen cross-linking (CXL) in infectious keratitis

Group 2To analyse the profile of microbial keratitis occurring after CXL

Page 3: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Riboflavin + UV A radiation

Irreversible breaks in DNA / RNA strands

Increases the corneal thermal shrinkage temperature

Effect on leucocytes

Effect on immune response

KXL in infectious keratitis: Mechanism

Kills microbes

Arrests stromal melting Reduces pain and

inflammation

Reactive Oxygen species

Page 4: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Non-healing microbial keratitis

Phase 1 of study Conventional CXL

15 eyes of 15 patients

Phase 2 of study (ongoing) Accelerated CXL

3 eyes of 3 patients

Not responding to 2 weeks of topical therapy

Prospective, interventional ongoing study

METHODOLOGY – GROUP1

Page 5: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Soak period0.1% Riboflavin

drops (Medio-Cross D) every 2 minutes for 30 minutes

Accelerated CXL in 3 patients 9mW/cm2 for 10

min

PROCEDURE

Conventional CXL – 15 patients 3mW/cm2 for 30

minutes

Riboflavin + UV-A (365nm)Irradiation

Page 6: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

RESULTSTotal resolution: Seen in 18 patients

8 out of 11 bacterial keratitis (72.73%) showed resolution

3 out of 6 fungal keratitis (50%) showed resolution

Acanthoemeba keratitis: Favourable result but

recurrence noted Can repeat CXL be

effective???

Superficial and anterior stromal infiltrates- better response

1st POD- significantly reduced/ no pain in all patients ‘Chemical denervation’

Mean time for epithelial healing- 23 days Mean time for resolution of corneal infiltrate was 33 days

Page 7: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Not every story has a Happy Ending….It is interesting that CXL itself might be a

precipitating factor in causing keratitis

Page 8: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Group 2To analyse the profile of microbial keratitis occurring after

CXL

4 eyes developed infectious keratitis post CXLEtiology - moxifloxacin resistant Staphylococcus aureus (MXRSA)

These eyes were studied

1715 CXL, 310 TE-CXL and 325 A-CXL over 7 years who underwent CXL

2350 progressive KC patients

A Retrospective analysis

Page 9: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Case Clinical picture Associated

conditionsTreatment Procedure Management

1 Bronchial asthma Inhalational /oral steroids

Conventional CXL

Femtosecond Endothelial Keratoplasty

2 Vernal catarrh Topical steroids Conventional CXL

Rigid gas permeable contact lens

3 Eczema Oral Cyclophospha-mide

Conventional CXL

Penetrating Keratoplasty

4 Vernal catarrh Topical steroids Conventional CXL

Amniotic membrane graft , under follow-up

Keratitis after CXL - Clinical profile of patients

Page 10: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

The Question Arises…

Cross –linking is treatment of

infectious keratitis

Cross-linking predisposing to keratitis

Page 11: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Pre –operative steroids:? altered flora

Ermis SS, Aktepe OC, Inan UU, Ozturk F, Altindis M. Effect of topical dexamethasone and ciprofloxacin on bacterial flora of healthy conjunctiva. Eye (Lond). 2004 Mar; 18(3):249-52

SYSTEMIC IMMUNOSUPPRESSION

LOCAL STEROID THERAPY

UVA induced:? Moxifloxacin

resistance

Ince D, Zhang X, Hooper DC. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother. 2003 Apr;47(4):1410-5

Page 12: Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.

Thank you